BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Milvexian readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Milvexian\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05757869-11184@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261209
SUMMARY:Milvexian: Phase 3 readout est. (NCT05757869)
DESCRIPTION:Milvexian\, phase 3.\nStudy: A Study of Milvexian Versus Apixab
 an in Participants With Atrial Fibrillation\nEstimated primary completion:
  8 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mil
 vexian#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05757869
URL:https://assetmemo.bio/drug/milvexian#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
